Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06209580 | AMT-253 in Patients With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 96 | Multitude Therapeutics Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04685226 | A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 310 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06907043 |
| A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.(EIK1004-001) |
| recruiting |
| Phase 1 / Phase 2 |
| 130 |
| Eikon TherapeuticsINDUSTRY |
| 3 |
| Aug 19, 2025 |
| clinicaltrials |
| NCT05761223 | A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | recruiting | Phase 1 / Phase 2 | 151 | 1ST Biotherapeutics, Inc.INDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06376136 | A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors | recruiting | Phase 1 / Phase 2 | 216 | Bio-Thera SolutionsINDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07070349 | A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 48 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07107633 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor. | recruiting | Phase 2 | 90 | Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.OTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06543056 | A Study of ES014 in Subjects With Advanced Solid Tumors | recruiting | Phase 2 | 15 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06208410 | A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 306 | Risen (Suzhou) Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05978102 | A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 183 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06277219 | A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)(LIGHTSPEED-1) | recruiting | Phase 1 / Phase 2 | 150 | Latticon Antibody Therapeutics, IncINDUSTRY | 2 | Jul 8, 2025 | clinicaltrials |
| NCT07050641 | Phase I/II Study of SCTB39-1 in Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 110 | Sinocelltech Ltd.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06669117 | FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations | recruiting | Phase 1 / Phase 2 | 140 | Pierre Fabre MedicamentINDUSTRY | 9 | Jul 2, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT06987500 | A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment | recruiting | Phase 1 / Phase 2 | 132 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06653777 | Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells(AcSé PEMI) | recruiting | Phase 2 | 40 | UNICANCEROTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06603844 | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | recruiting | Phase 1 / Phase 2 | 156 | Corbus Pharmaceuticals Inc.INDUSTRY | 2 | Jun 3, 2025 | clinicaltrials |
| NCT06943820 | AK129 Combination Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | AkesoINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05541822 | To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation | recruiting | Phase 2 | 178 | Abion IncINDUSTRY | 3 | May 22, 2025 | clinicaltrials |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06971523 | A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies | recruiting | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT05263960 | A Study of CM350 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 248 | Keymed Biosciences Co.LtdINDUSTRY | 1 | May 4, 2025 | clinicaltrials |
| NCT06669975 | A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 85 | AP Biosciences Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06895928 | A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors | recruiting | Phase 2 | 400 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04775485 | A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors(FIREFLY-1) | recruiting | Phase 2 | 141 | Day One Biopharmaceuticals, Inc.INDUSTRY | 11 | Apr 10, 2025 | clinicaltrials |
| NCT06431243 | A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06911333 | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors(AD1208) | recruiting | Phase 1 / Phase 2 | 36 | Avelos Therapeutics Inc.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05269316 | Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 61 | Impact Therapeutics, Inc.INDUSTRY | 4 | Apr 1, 2025 | clinicaltrials |
| NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 140 | TiumBio Co., Ltd.INDUSTRY | 2 | Mar 30, 2025 | clinicaltrials |
| NCT06895733 | Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) | recruiting | Phase 1 / Phase 2 | 65 | Tianjin Medical University Second HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05146440 | Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor(PRIME) | recruiting | Phase 1 / Phase 2 | 195 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05970016 | A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. | recruiting | Phase 1 / Phase 2 | 56 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05142423 | A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 198 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05487170 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | recruiting | Phase 1 / Phase 2 | 32 | Ranok Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT06032845 | Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)(CASTLE-11) | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06173219 | Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors. | recruiting | Phase 1 / Phase 2 | 38 | China-Japan Friendship HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04785196 | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 95 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06464055 | A Study of GQ1010 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | GeneQuantum Healthcare (Suzhou) Co., Ltd.INDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06549946 | Ixovex-1 Single Agent and Combination Therapy(IXACT) | recruiting | Phase 1 / Phase 2 | 18 | Psivac LtdINDUSTRY | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06038396 | A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 48 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05205850 | A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 135 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06016062 | A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 221 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06764628 | A Study of SHR-4375 in Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 208 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06782334 | AMT-116 in Patients with Solid Tumors | recruiting | Phase 1 / Phase 2 | 144 | Multitude Therapeutics Inc.INDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06600022 | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. | recruiting | Phase 1 / Phase 2 | 441 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 5, 2025source: clinicaltrials